Cascadian Therapeutics is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is tucatinib (ONT-380), an orally active and selective small molecule HER2 inhibitor. We are also developing a Chk1 inhibitor as a preclinical product candidate.